ArticleCancer research2008
A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells.
Article in Cancer research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 53 citations in OpenAlex.
- The p130Cas-Crk/CrkL Axis: A Therapeutic Target for Invasive Cancers Unveiled by Collaboration Among p130Cas, Crk, and CrkL.International journal of molecular sciences · 2025Review
- Rutin and Quercetin Counter Doxorubicin-Induced Liver Toxicity in Wistar RatsOxidative medicine and cellular longevity · 2022Article
- p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy.International journal of molecular sciences · 2021Article
- Classification of Homo sapiens gene behavior using linear discriminant analysis fused with minimum entropy mapping.Medical & biological engineering & computing · 2021Article
- Knockdown of lncRNA FOXD2-AS1 Inhibits Proliferation, Migration, and Drug Resistance of Breast Cancer Cells.Computational and mathematical methods in medicine · 2021Article
- Methanol Extract of Aerial Parts ofMolecules (Basel, Switzerland) · 2019Article
- The interaction of p130Cas with PKN3 promotes malignant growth.Molecular oncology · 2019Article
- Possible Mechanisms of the Prevention of Doxorubicin Toxicity by Cichoric Acid-Antioxidant Nutrient.Nutrients · 2018Article
- The miR-24-3p/p130Cas: a novel axis regulating the migration and invasion of cancer cells.Scientific reports · 2017Article
- A truncated phosphorylated p130Cas substrate domain is sufficient to drive breast cancer growth and metastasis formation in vivo.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Downregulation of microRNA-362-3p and microRNA-329 promotes tumor progression in human breast cancer.Cell death and differentiation · 2016Article
- Melatonin Prevents Mitochondrial Damage Induced by Doxorubicin in Mouse Fibroblasts Through Ampk-Ppar Gamma-Dependent Mechanisms.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.Oncotarget · 2016Article
- Identification of Novel Crk-associated Substrate (p130Cas) Variants with Functionally Distinct Focal Adhesion Kinase Binding Activities.The Journal of biological chemistry · 2015Article
- SRChing for the substrates of Src.Oncogene · 2014Review
- Association of the breast cancer antiestrogen resistance protein 1 (BCAR1) and BCAR3 scaffolding proteins in cell signaling and antiestrogen resistance.The Journal of biological chemistry · 2014Article
- MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.PloS one · 2013Article
- p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells.Breast cancer research : BCR · 2012Article
- A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.American journal of respiratory and critical care medicine · 2012Article
- Cas and NEDD9 Contribute to Tumor Progression through Dynamic Regulation of the Cytoskeleton.Genes & cancer · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Resistance to chemotherapy remains a major obstacle for the treatment of breast cancer. Understanding the molecular mechanism(s) of resistance is crucial for the development of new effective therapies to treat this disease. This study examines the putative role of p130(Cas) (Cas) in resistance to the cytotoxic agent Adriamycin. High expression of Cas in primary breast tumors is associated with the failure to respond to the antiestrogen tamoxifen and poor prognosis, highlighting the potential clinical importance of this molecule. Here, we show a novel association between Cas and resistance to Adriamycin. We show that Cas overexpression renders MCF-7 breast cancer cells less sensitive to the growth inhibitory and proapoptotic effects of Adriamycin. The catalytic activity of the nonreceptor tyrosine kinase c-Src, but not the epidermal growth factor receptor, is critical for Cas-mediated protection from Adriamycin-induced death. The phosphorylation of Akt and extracellular signal-regulated kinase 1/2 (ERK1/2) is elevated in Cas-overexpressing cells treated with Adriamycin, whereas expression of the proapoptotic protein Bak is decreased. Conversely, Cas depletion in the more resistant T47D and MDA-MB-231 cell lines increases sensitivity to Adriamycin. Based on these data, we propose that Cas activates growth and survival pathways regulated by c-Src, Akt, and ERK1/2 that lead to the inhibition of mitochondrial-mediated apoptosis in the presence of Adriamycin. Because Cas is frequently expressed at high levels in breast cancers, these findings raise the possibility of resensitizing Cas-overexpressing tumors to chemotherapy through perturbation of Cas signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.